BELLBROOK LABS Introduces the TRANSCREENER™ UGT ASSAY
Moving Glucorindation into High Throughput Screening.
|•||Universal||One set of reagents for any UGT isoform.|
|•||Efficient||Thousands of compounds can be evaluated in one day.|
|•||Easy||Homogeneous “mix and read” assay format.|
|•||Cost-effective||Low volume assays in 96- or 384-well plates minimizing costs.|
|•||Robust||Z' factor values > 0.5.|
Transcreener™ UGT Assay is the first UGT assay developed for High Throughput Screening. One of the major challenges of the pharmaceutical industry is to better predict the pharmacokinetic and pharmacogenomic consequences of drug-metabolizing enzymes, key determinants in drug efficacy and safety.
A broad spectrum of drugs, including opioids, steroidal anti-inflammatories, and antidepressants, are eliminated or activated in the body by glucuronidation. To fulfill the immediate need for high throughput analysis of drug glucuronidation, BellBrook Labs has developed a universal UDPglucuronosyltransferase (UGT) assay. The Transcreener™ UGT Assay enables screening of all UGT isoforms and diverse acceptors using the same assay and reagents, because it relies on detection of the invariant reaction product, UDP. This fluorescence polarization assay measures UDP formed during UGT- catalyzed glucuronidation reactions. As UDP is produced, the AlexaFluor488®-labeled tracer is displaced from the antibody which decreases polarization.
Call 866-313-7881 for more information or to order the Transcreener™ UGT-488P Assay.
Biology at Work